Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohmmed Margni

Vascular Surgery Flint, MI Medical Doctor

NPI 1417113713 CMS profile 290584

1 Hurley Plz, Son, 5Th Floor, Flint, MI 48503

Open in the dashboard

General payments

$2,168

14 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohmmed Margni of Flint, MI is reported in the CMS Open Payments database as having received $2,168 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77 1
2022 General $88 1
2020 General $16 1
2019 General $1,987 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohmmed Margni
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mohmmed Margni were reported at $77. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mohmmed Margni Vascular Surgery median Middle half National median
2019 $1,987 $796 $226–$2,363 $163
2020 $16 $348 $118–$1,110 $114
2021 $0 $471 $158–$1,421 $132
2022 $88 $725 $222–$2,183 $149
2023 $0 $836 $257–$2,440 $160
2024 $0 $909 $252–$2,619 $164
2025 $77 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $1,815 8 payments
  2. Medtronic Vascular, Inc. $142 2 payments
  3. Cardiovascular Systems Inc. $88 1 payment
  4. Philips Electronics North America Corporation $77 1 payment
  5. Abbott Laboratories $30 1 payment
  6. Alexion Pharmaceuticals, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,620 6 payments
  2. Food and Beverage $548 8 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System $1,815 8 payments
  2. ENROUTE Transcarotid Stent System $1,815 8 payments
  3. ENHANCE Transcarotid Peripheral Access Kit $1,815 8 payments
  4. ENROUTE 0.014 Guidewire $1,815 8 payments
  5. HawkOne $142 2 payments
  6. Labosys $77 1 payment
  7. Perclose ProGlide suture mediated closure system $30 1 payment
  8. Ultomiris $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

674

Median for General Surgery: 59

Drug cost

$83,362

Median for General Surgery: $393

Branded share of claims

59.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 62 $60,501
Eliquis Apixaban Brand 23 $16,553
Clopidogrel Clopidogrel Bisulfate Brand 319 $5,608
Methylprednisolone Generic 250 $551
Atorvastatin Calcium Generic 20 $149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$734,177

Of which drugs: $674

Medicare patients

367

Average age 73

Services billed

4,341

205 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 49%
Chronic kidney disease 49%
Ischemic heart disease 45%
Heart failure 34%
Atrial fibrillation 31%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 85 1,836 $415
Injection, fentanyl citrate, 0.1 mg J3010 Office 89 182 $77
Injection, midazolam hydrochloride, per 1 mg J2250 Office 103 260 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record